Anti-leishmanial effect of itraconazole niosome on in vitro susceptibility of Leishmania tropica

Environmental Toxicology and Pharmacology

Volumn 38, Issue 1, 2014, Pages 205-211

  Khazaeli, Payam ^a   Sharifi, Iraj ^b   Talebian, Elham ^a   Heravi, Gioia ^a   Moazeni, Esmaeil ^a   Mostafavi, Mahshid ^b  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Itraconazole; Leishmania tropica; Macrophage model; MTT assay; Niosome

Indexed keywords

ANTIMONY TARTRATE; ITRACONAZOLE; NIOSOME; ANTIPROTOZOAL AGENT; CHOLESTEROL; HEXOSE; LIPOSOME; SORBITAN STEARATE;

ANTIBIOTIC SENSITIVITY; ANTILEISHMANIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GROWTH RATE; IC 50; IN VITRO STUDY; LEISHMANIA TROPICA; MACROPHAGE; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; PROMASTIGOTE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG RELEASE; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; PERITONEUM MACROPHAGE;

ANIMALS; ANTIPROTOZOAL AGENTS; CHOLESTEROL; DRUG LIBERATION; HEXOSES; ITRACONAZOLE; LEISHMANIA TROPICA; LIPOSOMES; MACROPHAGES, PERITONEAL; MICE, INBRED BALB C;

EID: 84904627157     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2014.04.003     Document Type: Article

References (20)

1. Alvar J., Vélez I.D., Bern C., Herrero M., Desjeux P., Cano J., Jannin J., Den Boer M. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 2012, 7:e35671. WHO Leishmaniasis Control Team.
2. Baroni A., Aiello F.S., Vozza A., Vozza G., Faccenda F., Brasiello M., Ruocco E. Cutaneous leishmaniasis treated with itraconazole. Dermatol. Ther. 2009, 22:27-29.
3. Carrio M.C., Reiva C., Gallego M., Arboix M., Portus M. Leishmania infantum: stage specific activity of pentavalent antimony related with the assay conditions. Exp. Parasitol. 2000, 95:209-214.
4. Consigli J., Danielo C., Gallerano V., Papa M., Guidi A. Cutaneous leishmaniasis: successful treatment with itraconazole. Int. J. Dermatol. 2006, 45:46-49.
5. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006, 19:11-26.
6. Da Silva S.M., Amorim I.F., Ribeiro R.R., Azevedo E.G., Demicheli C., Melo M.N., Tafuri W.L., Gontijo N.F., Michalick M.S., Frézard F. Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis. Antimicrob. Agents Chemother. 2012, 56:2858-2867.
7. De Beule K., Cauwenberg G. Treatment of cutaneous leishmaniasis with ketoconazole and itraconazole. Recent Advances in Chemotherapy 1989, 612.1-612.2. Lewin-Epstein, Ltd., Jerusalem. E. Rubinstein, D. Adam (Eds.).
8. Hadighi R., Mohebali M., Boucher P., Hajjaran H., Khamesipour A., Ouellette M. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006, 3:659-667.
9. Jeddi F., Piarroux R., Mary C.H. Antimony resistance in Leishmania, focusing on experimental. J. Trop. Med. 2011, 69:53-82.
10. Nassiri-Kashani M., Firooz A., Khamesipour A., Mojtahed F., Nilforoushzadeh M., Hejazi H., Bouzari N., Dowlati Y. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J. Eur. Acad. Dermatol. Venereol. 2005, 19:80-83.
11. Noazin S., Khamesipour A., Moulton L.H., Tanner M., Nasseri K., Modabber F., Sharifi I., Khalil E.A., Bernal I.D., Antunes C.M., Smith P.G. Vaccine 2009, 27:4747-4753.
12. Pardakhty A., Varshosaz J., Rouholamini A. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int. J. Pharm. 2007, 328:130-141.
13. Pourmohammadi B., Motazedian M.H., Handjani F., Hatam G.H., Habibi S., Sarkari B. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis, Southeast Asian. J. Trop. Med. Public Health 2011, 42:502-508.
14. Rogerson A., Cumming J., Florence A.T. Adriamycin-loaded niosomes: drug entrapment, stability and release. J. Micro. Encap. 1987, 4:321-328.
15. Seifert K. Structures, targets and recent approaches in anti-leishmanial drug discovery and development. Open. Med. Chem. J. 2011, 5:31-39.
16. Srinivas N., Palne S., Nishi G.S., Bhandari K. Aryloxy cyclohexyl imidazoles: a novel of antileishmanial agent. Bioorg. Med. Chem. 2009, 19:324-327.
17. Uchegbu I.F., Florence A.T. Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv. Interface Sci. 1995, 58:1-55.
18. Wagh V.D., Deshmukh O.J. Niosomes as an ophthalmic drug delivery system: a review. J. Pharm. Res. 2010, 3:1558-1563.
19. Wagh V.D., Deshmukh O.J. Itraconazole niosomes drug delivery system and its antimycotic activity against Candida albicans. Int. Scholarly Res. Netw. 2012, 10.5402/2012/653465.
20. World Health Organization (WHO) Control of the Leishmaniases, Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases. WHO Technical Report Series 949, Geneva 2010, 1-187.